Hunan Nucien Pharmaceutical Co. Ltd.SSE: 688189

Announcement on Progress in the Strategic Restructuring of Controlling Shareholders

Jun 18, 2026 · Issued by Hunan Nucien Pharmaceutical Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Jun 18, 2026 · 2 pages · Chinese

On 6ix: 6ix.com/news/announcement-on-progress-in-the-strategic-restructuring-of-controlling-shareholders-2

Release

Announcement on Progress in the Strategic Restructuring of Controlling Shareholders

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Hunan Nucien Pharmaceutical Co. Ltd. on 6ix

Earlier from Hunan Nucien Pharmaceutical

Announcement on Obtaining Drug Registration Certificate for Levosalbutamol Hydrochloride Nebuliser SolutionJun 17
Announcement on Voluntary Disclosure of Phase III Clinical Trial of Peramivir Inhalation Solution Reaching Prespecified Primary EndpointJun 12
Announcement on Receiving the Prior Notice of Administrative PenaltyJun 10
Announcement on Progress in Transfer of Partial Accounts Receivable and Related Party TransactionsJun 2
Announcement on Resolutions of the 2025 Annual General MeetingMay 23

Later from Hunan Nucien Pharmaceutical

Announcement on Receipt of Drug Registration Acceptance NoticeJun 23
Announcement on Implementing Cancellation of Repurchased Shares and Share ChangesJul 9
Announcement on Abnormal Fluctuations in Stock TradingJul 15
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual ReportJul 16
Announcement on Reduction of Registered Capital, Amendment of the Articles of Association, and Completion of Industrial and Commercial Registration ChangesAug 11

All Hunan Nucien Pharmaceutical news releases

Follow Hunan Nucien Pharmaceutical into a list and get an email when it puts out news.

Follow Hunan Nucien Pharmaceutical